Abonnement à la biblothèque: Guest
Portail numérique Bibliothèque numérique eBooks Revues Références et comptes rendus Collections
Critical Reviews™ in Immunology
Facteur d'impact: 1.352 Facteur d'impact sur 5 ans: 3.347 SJR: 0.657 SNIP: 0.55 CiteScore™: 2.19

ISSN Imprimer: 1040-8401
ISSN En ligne: 2162-6472

Volumes:
Volume 39, 2019 Volume 38, 2018 Volume 37, 2017 Volume 36, 2016 Volume 35, 2015 Volume 34, 2014 Volume 33, 2013 Volume 32, 2012 Volume 31, 2011 Volume 30, 2010 Volume 29, 2009 Volume 28, 2008 Volume 27, 2007 Volume 26, 2006 Volume 25, 2005 Volume 24, 2004 Volume 23, 2003 Volume 22, 2002 Volume 21, 2001 Volume 20, 2000 Volume 19, 1999 Volume 18, 1998 Volume 17, 1997 Volume 16, 1996 Volume 15, 1995 Volume 14, 1994

Critical Reviews™ in Immunology

DOI: 10.1615/CritRevImmunol.v29.i6.10
pages 443-468

Regulation of Allergy with RNA Interference

Motohiko Suzuki
Departments of Surgery and Pathology, University of Western Ontario, London, Ontario, Canada; Department of Otorhinolaryngology, Nagoya City University, Nagoya, Japan
Xiufen Zheng
Departments of Surgery and Pathology, University of Western Ontario, London, Ontario
Xusheng Zhang
Departments of Surgery and Pathology, University of Western Ontario, London, Ontario
Yuwei Zhang
Medistem Laboratories, San Diego, CA
Thomas E. Ichim
Departments of Surgery and Pathology, University of Western Ontario, London, Ontario, Canada; Medistem Laboratories, San Diego, CA
Weiping Min
Departments of Surgery and Pathology, University of Western Ontario, London, Ontario

RÉSUMÉ

Allergic diseases such as asthma, allergic rhinitis, allergic conjunctivitis, and atopic dermatitis are clinically challenging. Although current treatments such as antihistamines, leukotriene receptor antagonists, and corticosteroids are effective at reducing symptoms, they do not address the underlying cause of the allergic response. Therefore, novel therapies that target upstream causative events in allergic diseases are desirable. The induction of RNA interference (RNAi) by small interfering RNA (siRNA) is a potent method for specifically knocking down molecular targets. Gene modulation by siRNA is therapeutically promising, with clinical safety and feasibility already demonstrated. However, to our knowledge, the use of siRNA in the area of allergic disease has been limited. Recently, we demonstrated the inhibition of CD40 by siRNA as a means of inhibiting allergic reactions. RNAi-based therapies represent a novel and promising strategy for the control of both the symptoms of allergy and the cause of the allergic response. Here we discuss the potential of siRNA in the treatment of allergic diseases by focusing on molecular and cellular interactions involved in the allergic cascade.